Publications

2016

J. Roh, G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588.
 
H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24.
 
V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6(40), 42411-42428.
 

2015

E. Potůčková, J. Roh, M. Macháček, S. Sahni, J. Stariat, V. Šesták, H. Jansová, P. Hašková, A. Jirkovská, K. Vávrová, P. Kovaříková, D. S. Kalinowski, D. R. Richardson, T. Šimůnek. In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE 2015, 10(10). e0139929.
 

A. Jirkovska, J. Roh, O. Lenčová-Popelová, E. Jirkovsky, K. Hruskova, E. Potuckova, H. Jansova, P. Haskova, P. Martinkova, T. Eisner, M. Kratochvil, J. Sus, M. Machacek, L. Tichotova, V. Gersl, D. S. Kalinowski, M. Muller, D. Richardson, K. Vavrova, M. Sterba, T. Simunek. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol. Res. 2015, 4, 1098-1114.

2014

Stariat J, Suprunova V, Roh J, Sestak V, Eisner T, Filipsky T, Mladenka P, Nobilis M, Simunek T, Klimes J, Kalinowski DS, Richardson DR, Kovarikova P. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomed. Chromatogr. 2014, 28(5), 621-629.

 

2012

Macková E, Hrušková K, Bendová P, Vávrová A, Jansová H, Hašková P, Kovaříková P, Vávrová K, Šimůnek T*. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action. Chem.-Biol. Interact. 2012; 197(2–3):69-79.

Stariat J, Šesták V, Vávrová K, Nobilis M, Kollárová Z, Klimeš J, Kalinowski DS, Richardson DR, Kovaříková P*. LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Anal. Bioanal. Chem. 2012, 403(1):309-321.

 

2011

Hašková P, Koubková L, Vávrová A, Macková E, Hrušková K, Kovaříková P, Vávrová K, Šimůnek T*. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicology 2011, 289(2-3):122-131.

Hrušková K, Kovaříková P, Bendová P, Hašková P, Macková E, Stariat J, Vávrová A, Vávrová K*, Šimůnek T*. Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis. Chem. Res. Toxicol. 2011; 24(3):290-302.

Kovaříková P*, Stariat J, Klimeš J, Hrušková K, Vávrová K. Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites - the cardioprotectant dexrazoxane as a model case. J. Chrom. A 2011; 1218(3):416-426.

 

2010

Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, Simunek T*. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem. Res. Toxicol. 2010; 23(6):1105-14.

 

© 2017 Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico